| B cells are associated with survival and immunotherapy response in sarcoma | Nature | 2020 | 538 |
| Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial | JAMA Oncology | 2020 | 274 |
| Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study | Lancet Oncology, The | 2020 | 148 |
| TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer | Annals of Oncology | 2020 | 142 |
| Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma | Journal of Hepatology | 2020 | 133 |
| Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases | Journal of Thoracic Oncology | 2020 | 77 |
| Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study | Lancet Oncology, The | 2020 | 71 |
| Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO | Annals of Oncology | 2020 | 64 |
| Precision Management of Advanced Non-Small Cell Lung Cancer | Annual Review of Medicine | 2020 | 52 |
| Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma | Journal of Hepatology | 2020 | 50 |
| Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial | Journal of Thoracic Oncology | 2020 | 46 |
| Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial | Journal of Thoracic Oncology | 2020 | 36 |
| Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma | Liver Cancer | 2020 | 34 |
| Gallic Acid Attenuated LPS-Induced Neuroinflammation: Protein Aggregation and Necroptosis | Molecular Neurobiology | 2020 | 34 |
| Platinum(II) Drug-Loaded Gold Nanoshells for Chemo-Photothermal Therapy in Colorectal Cancer | ACS Applied Materials & Interfaces | 2020 | 33 |
| Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS | Annals of Oncology | 2020 | 29 |
| Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer | Journal of Thoracic Oncology | 2020 | 29 |
| Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors | European Journal of Cancer | 2020 | 28 |
| Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study | Lancet Respiratory Medicine,the | 2020 | 26 |
| Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer | Gastric Cancer | 2020 | 26 |
| Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer | Cancer Science | 2020 | 23 |
| Sequential afatinib and osimertinib in patients with mutation-positive non-small-cell lung cancer: final analysis of the GioTag study | Future Oncology | 2020 | 23 |
| Disparity in Tumor Immune Microenvironment of Breast Cancer and Prognostic Impact: Asian Versus Western Populations | Oncologist | 2020 | 21 |
| A case-control study of perfluoroalkyl substances and the risk of breast cancer in Taiwanese women | Environment International | 2020 | 18 |
| Reliability of a single-region sample to evaluate tumor immune microenvironment in hepatocellular carcinoma | Journal of Hepatology | 2020 | 18 |
